146 related articles for article (PubMed ID: 38217968)
1. Antiviral therapy with tenofovir in MS.
Torkildsen Ø; Myhr KM; Brugger-Synnes P; Bjørnevik K
Mult Scler Relat Disord; 2024 Mar; 83():105436. PubMed ID: 38217968
[TBL] [Abstract][Full Text] [Related]
2. Tenofovir prodrugs potently inhibit Epstein-Barr virus lytic DNA replication by targeting the viral DNA polymerase.
Drosu NC; Edelman ER; Housman DE
Proc Natl Acad Sci U S A; 2020 Jun; 117(22):12368-12374. PubMed ID: 32409608
[TBL] [Abstract][Full Text] [Related]
3. Tenofovir as a treatment option for multiple sclerosis.
Torkildsen Ø; Myhr KM; Skogen V; Steffensen LH; Bjørnevik K
Mult Scler Relat Disord; 2020 Nov; 46():102569. PubMed ID: 33049462
[TBL] [Abstract][Full Text] [Related]
4. Chidamide Induces Epstein-Barr Virus (EBV) Lytic Infection and Acts Synergistically with Tenofovir to Eliminate EBV-Positive Burkitt Lymphoma.
Xu L; Zhang M; Tu D; Lu Z; Lu T; Ma D; Zhou Y; Zhang S; Ma Y; Yan D; Wang X; Sang W
J Pharmacol Exp Ther; 2023 Dec; 387(3):288-298. PubMed ID: 37875309
[TBL] [Abstract][Full Text] [Related]
5. Teriflunomide and Epstein-Barr virus in a Spanish multiple sclerosis cohort:
Domínguez-Mozo MI; González-Suárez I; Villar LM; Costa-Frossard L; Villarrubia N; Aladro Y; Pilo B; Montalbán X; Comabella M; Casanova-Peño I; Martínez-Ginés ML; García-Domínguez JM; García-Martínez MÁ; Arroyo R; Álvarez-Lafuente R
Front Immunol; 2023; 14():1248182. PubMed ID: 37841253
[TBL] [Abstract][Full Text] [Related]
6. Epstein-Barr Virus-Specific CD8 T Cells Selectively Infiltrate the Brain in Multiple Sclerosis and Interact Locally with Virus-Infected Cells: Clue for a Virus-Driven Immunopathological Mechanism.
Serafini B; Rosicarelli B; Veroni C; Mazzola GA; Aloisi F
J Virol; 2019 Dec; 93(24):. PubMed ID: 31578295
[TBL] [Abstract][Full Text] [Related]
7. Prazoles Targeting Tsg101 Inhibit Release of Epstein-Barr Virus following Reactivation from Latency.
Mannemuddhu SS; Xu H; Bleck CKE; Tjandra N; Carter C; Bhaduri-McIntosh S
J Virol; 2021 Jun; 95(13):e0246620. PubMed ID: 33853959
[TBL] [Abstract][Full Text] [Related]
8. Humoral response to Epstein-Barr virus in patients with multiple sclerosis treated with B cell depletion therapy.
Rød BE; Wergeland S; Bjørnevik K; Holmøy T; Ulvestad E; Njølstad G; Myhr KM; Torkildsen Ø
Mult Scler Relat Disord; 2023 Nov; 79():105037. PubMed ID: 37804765
[TBL] [Abstract][Full Text] [Related]
9. MINI-review of Epstein-Barr virus involvement in multiple sclerosis etiology and pathogenesis.
Aloisi F; Cross AH
J Neuroimmunol; 2022 Oct; 371():577935. PubMed ID: 35931008
[TBL] [Abstract][Full Text] [Related]
10. Interferon β1a treatment does not influence serum Epstein-Barr virus antibodies in patients with multiple sclerosis.
Lie IA; Rød BE; Kvistad SS; Holmøy T; Myhr KM; Torkildsen Ø; Wergeland S
Mult Scler Relat Disord; 2023 Feb; 70():104530. PubMed ID: 36701908
[TBL] [Abstract][Full Text] [Related]
11. Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI.
Farrell RA; Antony D; Wall GR; Clark DA; Fisniku L; Swanton J; Khaleeli Z; Schmierer K; Miller DH; Giovannoni G
Neurology; 2009 Jul; 73(1):32-8. PubMed ID: 19458321
[TBL] [Abstract][Full Text] [Related]
12. Markers of Epstein-Barr virus and Human Herpesvirus-6 infection and multiple sclerosis clinical progression.
Tao C; Simpson-Yap S; Taylor B; Blizzard L; Lucas R; Ponsonby AL; Broadley S; van der Mei I;
Mult Scler Relat Disord; 2022 Mar; 59():103561. PubMed ID: 35131728
[TBL] [Abstract][Full Text] [Related]
13. Diversification and expansion of the EBV-reactive cytotoxic T lymphocyte repertoire following autologous haematopoietic stem cell transplant for multiple sclerosis.
Massey J; Artuz C; Dyer Z; Jackson K; Khoo M; Visweswaran M; Withers B; Moore J; Ma D; Sutton I
Clin Immunol; 2023 Sep; 254():109709. PubMed ID: 37495004
[TBL] [Abstract][Full Text] [Related]
14. NF-kappaB inhibitors induce lytic cytotoxicity in Epstein-Barr virus-positive nasopharyngeal carcinoma cells.
Liu SF; Wang H; Lin XC; Xiang H; Deng XY; Li W; Tang M; Cao Y
Cell Biol Int; 2008 Aug; 32(8):1006-13. PubMed ID: 18579417
[TBL] [Abstract][Full Text] [Related]
15. A Mechanism-Based Targeted Screen To Identify Epstein-Barr Virus-Directed Antiviral Agents.
Li X; Akinyemi IA; You JK; Rezaei MA; Li C; McIntosh MT; Del Poeta M; Bhaduri-McIntosh S
J Virol; 2020 Oct; 94(21):. PubMed ID: 32796077
[TBL] [Abstract][Full Text] [Related]
16. In the era of antiviral trials for MS, the answer lies in the details.
Drosu N; Bjornevik K; Bilodeau PA; Yeh A; Lechner-Scott J; Hawkes CH; Giovannoni G; Levy M
Mult Scler Relat Disord; 2024 Feb; 82():105444. PubMed ID: 38241758
[No Abstract] [Full Text] [Related]
17. Valpromide Inhibits Lytic Cycle Reactivation of Epstein-Barr Virus.
Gorres KL; Daigle D; Mohanram S; McInerney GE; Lyons DE; Miller G
mBio; 2016 Mar; 7(2):e00113. PubMed ID: 26933051
[TBL] [Abstract][Full Text] [Related]
18. A different response to cytomegalovirus (CMV) and Epstein-Barr virus (EBV) infection in UK people with multiple sclerosis (PwMS) compared to controls.
Maple PAC; Tanasescu R; Gran B; Constantinescu CS
J Infect; 2020 Mar; 80(3):320-325. PubMed ID: 31678173
[TBL] [Abstract][Full Text] [Related]
19. Increased CD8+ T cell response to Epstein-Barr virus lytic antigens in the active phase of multiple sclerosis.
Angelini DF; Serafini B; Piras E; Severa M; Coccia EM; Rosicarelli B; Ruggieri S; Gasperini C; Buttari F; Centonze D; Mechelli R; Salvetti M; Borsellino G; Aloisi F; Battistini L
PLoS Pathog; 2013; 9(4):e1003220. PubMed ID: 23592979
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Epstein-Barr virus reactivation in nasopharyngeal carcinoma cells by dietary sulforaphane.
Wu CC; Chuang HY; Lin CY; Chen YJ; Tsai WH; Fang CY; Huang SY; Chuang FY; Lin SF; Chang Y; Chen JY
Mol Carcinog; 2013 Dec; 52(12):946-58. PubMed ID: 22641235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
